PCSK9 inhibitors to treat hypercholesterolemia: no effect on stroke risk
A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin 9 ( PCSK9 ) inhibitors Alirocumab and Evolocumab.
Researchers have investigated the effect PCSK9 inhibition on stroke risk in a meta-analysis involving data from randomized studies with Alirocumab and Evolocumab.
Data from pre-specified combined analysis of 4465 patients who completed phase 2 or 3 studies of Evolocumab over a period of 1year and a randomized trial on Alirocumab including 2341 patients with hyperlipidemia on maximally tolerated statin who were at high risk for coronary heart disease over a period of 1.5years were used.
The number of patients having an ischemic stroke was small in both trials.
PCSK9 inhibition showed no significant effect on stroke rate ( risk ratio 1.43; 95% CI, 0.45-4.57, p=0.55 ).
No significant differences in stroke risk were evident when transient ischemic attacks were included in the analysis ( risk ratio 0.65; 95% CI, 0.25-1.68, p=0.37 ).
No hemorrhagic strokes were reported in either study.
Although a benefit towards reduction of cardiovascular events in the overall has been documented, longer exposure is warranted to be able to evaluate the effect on stroke risk. ( Xagena )
Milionis H et al, Eur J Intern Med 2016; Epub ahead of print
The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared...
European Union has approved Praluent to reduce the risk of cardiovascular events in patients with established cardiovascular disease
The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular (...
Praluent to prevent myocardial infarction, stroke and unstable angina requiring hospitalization, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...
Heterozygous familial hypercholesterolemia: individualized low-density lipoprotein cholesterol reduction with Alirocumab titration strategy
Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...
ODYSSEY Alirocumab trials: lower major adverse cardiovascular events risk with lower LDL cholesterol levels
In statin trials, men and women have shown similar relative risk reductions in cardiovascular events per 39 mg/dL low-density lipoprotein...
Long-term safety and efficacy of Alirocumab in patients with heterozygous familial hypercholesterolemia
ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...
Heterozygous familial hypercholesterolemia: 63% of patients treated with Alirocumab no longer required apheresis
Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...
Anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia: systematic review of published phase 3 data
Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...
ODYSSEY LONG TERM trial: robust and consistent LDL cholesterol lowering demonstrated with Alirocumab, a PCSK9 inhibitor
The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...